Phase I/II LIBRETTO-001 trial: RET inhibitor achieves durable objective responses across multiple tumors

The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.